SAN DIEGO, August 6, 2018 /PRNewswire/ – ProSciento, Inc., a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases, today announced the appointment of Brian Mooney to the role of Chief Operating Officer (COO). Mr. Mooney joins ProSciento from the CRO Chiltern, a Covance company, where he served as Executive Vice President, Strategic Service Provision.
As a member of the executive team, Mr. Mooney will lead operations for the company’s CRO and clinical research unit (CRU) divisions, as well as contribute to corporate strategy and senior client relationships. Dr. Linda Morrow, ProSciento’s COO since 2009, will transition to Chief Medical Officer, overseeing the company’s medical and scientific teams.
“We are thrilled to have Brian join ProSciento’s executive leadership team. Brian is a prominent and respected leader in the CRO industry. His experience and expertise in implementing global expansion strategies with a keen focus on systems, processes, efficiencies and quality has led to significant successes for companies like Chiltern, Theorem and PRA,” said Marcus Hompesch, MD, ProSciento’s Chief Executive Officer and Chairman of the Board. “Brian also possesses a collaborative, values-driven leadership style that we consider vitally important for our corporate culture.”
“ProSciento has cultivated exceptional scientific and operational expertise in clinical R&D for NASH, diabetes and obesity. This positions the company as one of the only specialty CROs providing full scope services for these therapeutic areas of significant importance to the healthcare community and drug developers,” said Brian Mooney, ProSciento’s newly appointed Chief Operating Officer. “I’m delighted to be part of the leadership team to support the continued growth of ProSciento and its contributions in advancing new treatments and new methodologies in these critical therapeutic areas.”
Mr. Mooney is a CRO executive with over 25 years of experience, much of it focused on global expansion of operations for mid to large CROs, including Chiltern, Theorem and Pharmaceutical Research Associates International (PRA). Prior to joining ProSciento, he served as Executive Vice President of Strategic Service Provision at Chiltern, a Covance company, where he oversaw the development and advancement of one of their core business segments. Before that, Mr. Mooney was Senior Vice President of Clinical Development and General Manager at Theorem Clinical Research (acquired by Chiltern in 2015) and oversaw the expansion and optimization of the clinical operations footprint at a time of rapid momentum for Theorem as a spin out from parent company Omnicare. Prior to his role at Theorem, over a period of 16 years, he held a succession of leadership positions at PRA, including Senior Vice President of Project Services; Vice President of Global Project Management; and Vice President of Countries Group. Over the course of his tenure at PRA, Mr. Mooney contributed significantly to the company’s global expansion of clinical operations, including implementation of PRA’s Global Project Management Methodology initiative and International Partners program. He received his bachelor’s degree in biology with a minor in chemistry from Trenton State College in Trenton, New Jersey.
About ProSciento, Inc.
ProSciento is a leading specialty clinical research organization (CRO) exclusively focused on NASH, diabetes, obesity and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 280 clinical projects for diabetes, NASH and obesity and supported the development of many approved metabolic drugs and devices on the market globally today.
For media inquiries, please contact:
Senior Director, Corporate Communications, ProSciento, Inc.
For business development inquires: